Loading
A phase 1/2 trial of Fludarabine and Cyclophosphamide in advanced solid tumours, run by Beijing Biotech, now recruiting.
Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07523529 by Beijing Biotech, with 72 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-04-14. Interventions recorded: Autologous dual-target CAR-T cells selected from the predefined target library., Fludarabine and Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Cyclophosphamide, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Fludarabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.